Form 4 for ORGO Organogenesis Holdings Inc.
Accepted 2023-02-24 00:00:00 ET · period of report 2023-02-22 · accession 0001062993-23-004887 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-24 | 2023-02-22 | ORGO | Gillheeney Gary S. | Pres, CEO, Dir | A - Grant | $0.00 | +896.4K | 1.77M | +102% | $0 |
| D | 2023-02-24 | 2023-02-22 | ORGO | Gillheeney Gary S. | Pres, CEO, Dir | A - Grant | $0.00 | +1.66M | 1.66M | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2023-02-22 | A | A | 896,414 | $0.00 | 1,774,402 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-02-22 | A | A | 1,655,381 | $0.00 | 1,655,381 | D | $2.51 · — to 2033-02-22 | 1,655,381 Class A Common Stock | (F2) The option becomes exercisable in equal annual installments over four years beginning February 15, 2023. |